ReShape Lifesciences Approves Asset Sale and Merger

ReShape Lifesciences ( (RSLS) ) has issued an announcement.

On August 7, 2025, ReShape Lifesciences Inc. held a reconvened special meeting of stockholders to finalize decisions on two key proposals. The stockholders approved the sale of substantially all of the company’s assets to Ninjour Health International Limited and adopted amendments to the company’s Restated Certificate of Incorporation in connection with a proposed merger with Vyome Therapeutics, Inc. These approvals are significant for the company’s strategic direction and potential industry positioning.

Spark’s Take on RSLS Stock

According to Spark, TipRanks’ AI Analyst, RSLS is a Underperform.

ReShape Lifesciences is facing significant financial challenges, with persistent losses, negative equity, and cash flow issues. The technical indicators show a bearish trend with potential oversold conditions. Valuation is poor due to a negative P/E ratio. Despite some positive developments highlighted in the earnings call, such as revenue growth and cost reductions, the overall outlook remains concerning due to financial instability and competitive pressures. The recent board resignation further complicates the situation by potentially affecting compliance and investor confidence.

To see Spark’s full report on RSLS stock, click here.

More about ReShape Lifesciences

ReShape Lifesciences Inc. operates in the healthcare industry, focusing on medical devices and solutions for weight loss and metabolic health.

Average Trading Volume: 2,610,260

Technical Sentiment Signal: Strong Sell

Current Market Cap: $5.34M

See more insights into RSLS stock on TipRanks’ Stock Analysis page.